comprehensive -WSS

comprehensive

author：Wikipedia 2025-10-02 20:49:24 - browse：77

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter:

The Food and Drug Administration’s decision in June to grant conditional approval to a gene therapy for Duchenne muscular dystrophy was a watershed moment for the treatment of the neuromuscular disease, and a big win for its maker, Sarepta Therapeutics. Confirming the gene therapy’s benefit — and potentially broadening its use to include older boys — will be determined by a Phase 3 clinical trial that will read out later this quarter.

Pfizeris developing its own gene therapy for Duchenne in a fully enrolled Phase 3 study with final results expected in 2024. But before the verdict is revealed, Pfizer intends to conduct an interim analysis later this quarter. The most likely outcome of this early look will be a determination to continue the study to its completion. But surprises — including an early stop for overwhelming efficacy — can’t be ruled out.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： Marvel Studios reveals new trailer for 'The Marvels': Watch here

leisure time

WSS

FDA clears Verve to begin U.S. study of gene

Questions loom on AstraZeneca cancer drug as safety concerns ebb

Caitlin Bernard's story shows physicians can't shy from advocacy

Roivant's CEO is a star, but biotech's black hole persists

CDC backtracks, saying fully vaccinated people can go maskless indoors

Vatican is moving ahead with plan to reunite Ukrainian children taken to Russia with their families

knowledge

comprehensive

Wikipedia

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

STAT Summit: Meghan O’Rourke on making chronic illness visible

State Dept. review finds Biden bears some blame for Afghanistan failures

Court strikes down limits on filming of police in Arizona

Duchenne breakthrough therapy leaves behind pioneering families

In new study, freeze

Sports medicine is finally prioritizing gender equality

Study on Amgen’s bispecific immunotherapy produces positive data

Cancer drug shortages should be causing more outrage

Smaller biotechs seek to piggyback on weight loss drug boom

explore

UnitedHealth, Optum discontinue NaviHealth name

Our daughter's deadly disease: trisomy 18. We wanted to protect her

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Review: 'Barbie' will hit you like a shot in the heart

Health tech investors get more selective as pandemic boom fades

Our daughter's deadly disease: trisomy 18. We wanted to protect her

hotspot

leisure time

entertainment

focus